- Second licensing agreement secured with AstraZeneca’s Japanese subsidiary for ResApp technology
- Extends use of cough counting from clinical research in lung cancer to a patient support program for asthma
- First time ResApp’s cough counting technology is being used outside of a clinical trial setting
- ResApp’s cough counting software development kit (SDK) to be integrated into AstraZeneca’s Asthma Monitoring App to support patients
- Cough counting SDK designed to measure frequency of patient coughs over extended periods – cough frequency can provide insight into the progression and management of respiratory disease
- Agreement is significant validation of ResApp’s technology from a leading global pharmaceutical company
Brisbane, Australia, 12 March 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has secured a one year, non-exclusive licensing agreement with AstraZeneca K.K. (“AstraZeneca”), the Japanese subsidiary of global biopharmaceutical company AstraZeneca PLC., to license its cough counting technology for use in a program to support asthma patients.
Under the agreement, ResApp’s cough counting technology will be integrated into AstraZeneca’s direct-to-consumer asthma management smartphone application, to assist patients in monitoring symptoms in the home setting and support them in managing their asthma.
AstraZeneca’s asthma monitoring application is currently under development and is expected to launch in the coming months. ResApp will work with AstraZeneca on the integration into the smartphone application, refining it to the group’s specifications for use in the Japanese market.
The agreement follows ResApp’s initial licensing agreement with AstraZeneca, secured in October 2020 (refer ASX announcement: 22 October 2020) for use of the cough counting technology in a lung cancer clinical trial. Pleasingly, this marks the first time ResApp’s cough counting technology is being used outside of a clinical trial setting, highlighting its broad applicability. The second agreement with AstraZeneca provides further validation from an industry-leading pharmaceutical company.
AstraZeneca will pay an annual licence fee to ResApp for each patient provided with AstraZeneca’s asthma management smartphone application. While sales of ResApp’s cough counting SDK continue to grow, the company does not expect this agreement to have a material impact on the company’s operating results.
Managing Director and CEO Dr Tony Keating said: “With its Asthma Monitoring App, AstraZeneca is seeking to empower and support patients to help them take control of their asthma. Over one million people in Japan live with asthma and AstraZeneca’s app aims to help patients better manage their condition and adhere to their management plans, leading to a better quality of life.
“We are proud to be an integral part of this initiative and look forward to working with AstraZeneca on the integration process and launch of this important patient support program.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.